Stereotactic body radiation therapy (SBRT) represents a novel treatment modality for cancer and has been used to treat various types of primary cancer with curative intent. Data on the use of SBRT for various primary sites are emerging. While the largest body of data is concerned with early-stage lung cancer, there is also a fair amount of experience in the treatment of nonpulmonary primary sites with SBRT. This article will provide an overview of radiobiologic, technical and clinical aspects of the use of this emerging treatment modality for various nonpulmonary primary tumors.